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Intestinal fibrostenosis is a hallmark of severe
Crohn’s disease and can lead to multiple surgeries.
Patients with certain TNFSF15 variants overexpress
TL1A. The aim of this study was to determine the
effect of TL1A overexpression on intestinal inflamma-
tion and the development of fibrostenosis. We as-
sessed the in vivo consequences of constitutive TL1A
expression on gut mucosal inflammation and fibro-
stenosis using two murine models of chronic colitis.
In the dextran sodium sulfate (DSS) and adoptive T-
cell transfer models, there was proximal migration of
colonic inflammation, worsened patchy intestinal in-
flammation, and long gross intestinal strictures in
Tl1a transgenic compared to wild-type littermates. In
the DSS model, myeloid- and T-cell–expressing Tl1a
transgenic mice had increased T-cell activation mark-
ers and interleukin-17 expression compared to wild-
type mice. In the T-cell transfer model, Rag1/mice
receiving Tl1a transgenic T cells had increased inter-
feron- expression but reduced T-helper 17 cells and
IL-17 production. Narrowed ureters with hydrone-
phrosis were found only in the Tl1a transgenic mice
in all chronic colitis models. In human translational
studies, Crohn’s disease patients with higher periph-
eral TL1A expression also exhibited intestinal fibro-
stenosis and worsened ileocecal inflammation with
relative sparing of rectosigmoid inflammation. These
636data show that TL1A is an important cytokine that not
only modulates the location and severity of mucosal
inflammation, but also induces fibrostenosis. (Am J
Pathol 2012, 180:636–649; DOI: 10.1016/j.ajpath.2011.10.026)
Crohn’s disease (CD) is a chronic inflammatory condition
with pathological features such as patchy transmural gut
inflammation and fibrostenosis with relative sparing of the
rectum.1,2 Fibrostenosis is a characteristic of severe, of-
ten treatment-resistant, disease, a source of significant
morbidity, and in nearly every case, requires surgical
intervention. Variants in the TNFSF15 gene have been
found to be associated with inflammatory bowel disease
(IBD); and its protein product, TL1A, is elevated in the
intestinal mucosa of IBD patients. Certain TNFSF15 hap-
lotypes are associated with susceptibility in non-Jewish
Caucasian CD and UC patients. In addition, TNFSF15
haplotype-B is not only associated with risk, but also with
severity in Jewish CD patients.3–5 Moreover, monocytes
from Jewish patients carrying the risk haplotype-B ex-
press higher peripheral monocyte TL1A expression in
response to FcR stimulation.3 These results show that
CD-associated TNFSF15 genetic variations contribute to
enhanced induction of TL1A, resulting in severe, chronic
mucosal inflammation- and that modulation of TL1A may
be a potential target for therapeutic development.
TL1A signals via death domain receptor 3 (DR3) and
modulates the adaptive immune response. In the
T-helper (Th)-1 effector arm, TL1A enhances interferon
(IFN)- production from peripheral and mucosal
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TL1A also plays a role in augmenting Th-2 and Th-17
effector cell function.8–11 The differential effect of TL1A
on Th-17 cells was demonstrated by a recent report
showing that TL1A inhibited Th-17 development in naive
T cells but maintained the effector characteristics of com-
mitted Th-17 cells.12
In addition to human reports, several studies in mice
also implicate the TL1A/DR3 signaling pathway in muco-
sal inflammation.13,14 Neutralizing TL1A antibody amelio-
rates inflammation in DSS and Gi2/ T-cell transfer
chronic colitis models.10 Additionally, constitutive TL1A
expression in mice leads to mild spontaneous ileitis and
increased collagen deposition.15–17
To determine the in vivo consequences of constitutive
TL1A expression under colitogenic settings, chronic dex-
tran sodium sulfate (DSS)-induced [myeloid and T-cell
Tl1a transgenic (Tg) mice] and adoptive-transfer (T-cell
Tl1a transgenic mice) models were used. In all models,
there was proximal migration of colonic inflammation,
worsened patchy intestinal inflammation, and strictures in
the intestine and colon with constitutive TL1A expression.
Similarly, CD patients with TNFSF15 haplotype-B and el-
evated TL1A expression in primary monocytes showed
worsened ileocecal inflammation with relative rectosig-
moid sparing and intestinal fibrostenosis. These novel
murine Tl1a-Tg models resemble a complicated form of
severe human CD. Results from these Tl1a-Tg experi-
mental models coupled with findings in CD patients sug-
gest that TNFSF15 is a severity gene and that the cyto-
kine, TL1A, when overexpressed, plays a central role in
generating one phenotypic form of complicated CD.
Materials and Methods
Transgenic Mice and Induction of Chronic
Colitis
LCK-CD2-Tl1a-GFP (L-Tg) and FMS-Tl1a-GFP Tg (M-Tg)
mice were generated and genotyped as described.17
Chronic DSS colitis was induced as described,10 except
2% (w/v) DSS (MP Biomedicals, Irvine, CA) drinking wa-
ter was used due to lethality in Tl1a-Tg mice when DSS
concentration 2.5% was used. In the adoptive-transfer
model, colitis was induced by intraperitoneal injection of
500,000 CD4CD45RBhi naive T cells isolated from either
L-Tg or wild-type (WT) mice to Rag1/ mice.18 All mice
were maintained under specific pathogen-free conditions
in the Animal Facility at Cedars-Sinai Medical Center
(CSMC). Littermate control mice were used. This study
was performed in strict accordance with the Guide for the
Care and Use of Laboratory Animals of the National In-
stitutes of Health. Animal studies were approved by the
CSMC Animal Care and Use Committee (protocol 2269).
Quantitation of DSS Water Consumption
WT, L-Tg, and M-Tg mice (n  5 in each group) were
housed individually in a cage and administered 2% DSS
water on days 1 to 5, 8 to 12, 15 to 19, and 22 to 26. Theweight of DSS water was measured at the beginning of
each cycle (days 1, 8, 15, and 22) and at the end of the
cycle (days 5, 12, 19, and 26). DSS water consumption
was measured by subtracting DSS water weight at the
beginning of the treatment cycle from the end of the
treatment cycle.
Disease Activity Index, Myeloperoxidase, and
Macroscopic and Histopathological Analyses
The disease activity index (DAI) was calculated by scor-
ing from 0 to 4 abnormalities regarding changes in body
weight (0, no weight loss; 1, 1% to 5% weight loss; 2, 5%
to 10% weight loss; 3, 10% to 15% weight loss; 4, more
than 15% weight loss), stool consistency (0, firm dry
stool; 1, moist stool; 2, soft adherent stool; 3, large soft
pliable stool; 4, liquid stool), stool blood performed on
Hemoccult Sensa (Beckman Coulter, Brea, CA; 0, no
color; 1, flecks of blue; 2, up to 50% blue; 3, more than
50% blue; 4, gross red blood), and summing the re-
sults.19 DAI was determined every other day for the DSS
model and twice a week for the adoptive-transfer model.
Myeloperoxidase activity was assessed using the
EnzChek Myeloperoxidase Activity Assay Kit according
to the manufacturer’s protocol (Invitrogen, Carlsbad, CA).
Macroscopic evidence of inflammation was scored
blinded to the mice genotype using the established clas-
sification.10,18 Briefly, normal gut morphology was as-
signed a score of 0; mild bowel wall thickening without
hyperemia was assigned a score of 1; moderate bowel
wall thickening with hyperemia was assigned a score of
2; severe bowel wall thickening with rigidity and hyper-
emia was assigned a score of 3; and severe bowel wall
thickening with rigidity, hyperemia, and adhesions was
assigned a score of 4. Samples were processed and
stained with hematoxylin and eosin (H&E) by the CSMC
Histology Core Laboratory. Masson-Trichrome and vi-
mentin staining were performed as described.20 Histo-
pathological scores of colons and intestine were as-
signed in a blinded manner by two trained animal
pathologists (D.Q.S. and H.W.K.) using established
methods.10,18 For the DSS model, histology was scored
as follows: inflammation (I): 0, none; 1, mild; 2, moderate;
3, severe; extent (E): 0, none; 1, mucosa; 2, mucosa and
submucosa; 3, transmural; regeneration (R): 0, complete
regeneration; 1, almost complete regeneration; 2, regen-
eration with crypt depletion; 3, surface epithelium not
intact; 4, no tissue repair; crypt damage (C): 0, none; 1,
basal one-third damaged; 2, basal two-thirds damaged;
3, only surface epithelium intact; 4, entire crypt and epi-
thelium lost; percentage involvement (P): 1, 1% to 25%; 2,
26% to 50%, 3, 51% to 75%, 4, 76% to 100%. Total
histology score is given as I  E  R  C  P. For the
adoptive-transfer model, histopathological assessments
of colons were scored as follows: inflammatory infiltrate in
lamina propria (I): 1, 1% to 25%; 2, 26% to 66%; 3, 66%
to 100%; mucin depletion (M): 0, normal; 1, up to 70%
depleted; 2, over 70% depleted; epithelial atypia (E): 0,
normal; 1, epithelial hyperplasia; 2, epithelial atypia; 3,
epithelial atypia with nuclear changes; crypt architecture
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complete loss; crypt abscess (A): 0, none; 1, few cells; 2,
abscess; ulceration (U): 0, normal; 1, erosion; 2, ulcer-
ation; depth of involvement (D): 1, to submucosa; 2,
transmural. Total colonic histology score for adoptive-
transfer model is given as I  M  E  C  A  U  D.
Histopathological scoring of small intestine in the adop-
tive transfer model was performed as follows: inflamma-
tion (I): 0, normal; 1, mild; 2, moderate; 3, severe; crypt
damage (C): 0, none; 1, basal one-third damaged; 2,
basal two-third damaged; 3, more than two-third dam-
ages; percent involvement (P): 1, mucosa; 2, submu-
cosa; 3, transmural; villus change (V): 0, normal; 1, dis-
tortion; 2, branching; 3, atrophy and blunting. The total
intestinal score for the adoptive- transfer model is given
as I  C  P  V. The histological score, vimentin-
positive cells, and collagen thickness were calculated
from observation of 10 different fields per gut region at
200 magnification from 10 mice in each group.
Expression Analysis
Total RNA was isolated and reverse-transcription poly-
merase chain reaction (RT-PCR) was performed as de-
scribed.21 -Actin, IGF-1, and TGF- mRNA were ampli-
fied as described.10,20 Amount of transcript was
analyzed and expressed as percentage of -actin. Cyto-
kine concentration was assayed by enzyme-linked immu-
nosorbent assay (ELISA) using kits for IFN-, IL-17, IL-13,
IL-6, and TNF (eBioscience, San Diego, CA) per the
manufacturer’s protocol.
Cell Isolation, Culture, Intracellular Cytokine
Expression, and Flow Cytometry
Isolation and culture of lamina propria mononuclear cells
(LPMC), mesenteric lymph node (MLN), and splenic cells
and their subsequent stimulation by anti-CD28 and anti-
CD3 were performed as reported.10 We used the whole
colon and the distal 10 cm of the ilea for LPMC isola-
tion. Intracellular staining and antibodies used were
described previously.17 Cells were acquired on a Cyan
flow cytometer (Dako-Cytomation, Carpinteria, CA) and
analyzed using FlowJo analysis software (Tree Star,
Ashland, OR).
Human Subjects
Patients enrolled in this study were seen at the CSMC
Inflammatory Bowel Disease Center and had been diag-
nosed with CD according to standard clinical, endo-
scopic, radiological, and histological findings. Written in-
formed consent was obtained and approved by the
CSMC Institutional Review Board (IRB nos. 3358 and
2673). Clinical course, laboratory values, and endo-
scopic findings were collected, and histology was
scored by two pathologists blinded to TL1A status
(D.Q.S. and M.V.). The biopsy specimens from the first
available colonoscopy at CSMC after IBD diagnosis
were used. Ten or more histological sections per gutregion from each patient were scored at 200 magni-
fication.22 Assessment of TL1A levels, genotyping, and
haplotype assignment had been performed.3 Patients
defined as high TL1A producers were Jewish subjects
with homozygous risk haplotype-B whose immune
complex–stimulated TL1A at 6 hours was 0.15 ng/
mL/1  106 peripheral monocytes. Patients defined as
low TL1A producers were Jewish subjects with ho-
mozygous protective haplotype-A whose immune com-
plex–stimulated TL1A at 6 hours was 0.15 ng/mL/1 
106 peripheral monocytes.
Statistical Analysis
Data are presented as the mean  SD. Comparison
between two groups was performed by a two-tailed Fish-
er’s exact test for categorical variables and Student’s
t-test for continuous variables. Parametric and nonpara-
metric tests were used depending on the fulfillment of the
test assumptions. Comparison between three groups
was done using analysis of variance test, followed by
pairwise post hoc analysis with Tukey’s HSD test and
Behrens-Fisher test correction for the multiple compari-
sons. P  0.05 was considered significant.
Results
Constitutive TL1A Expression Leads to
Reduced Weight in the Adoptive T-Cell
Transfer Model
DSS-induced and adoptive T-cell transfer models were
used to determine the in vivo consequences of TL1A
overexpression. Adaptive immunity plays an important
role in chronic colitis induced by multiple cycles of
DSS10,23 and by adoptively transferring naive
CD4CD45RBhi T cells into immune-deficient Rag1/
mice.18 No significant differences in weight were ob-
served in the DSS model (Figure 1A). In general, there
was no difference in disease activity index between WT
and Tg mice (data not shown). To determine that
changes in the disease activity index were not due to
differences in consumed DSS water between the different
mice groups, DSS water consumption was assessed. We
found that the quantity of consumed DSS water was sim-
ilar for each of the four DSS treatment cycles among the
different groups of mice (see Supplemental Figure S1 at
http://ajp.amjpathol.org).
In the adoptive-transfer model, Rag1/ mice that re-
ceived naive L-Tg (but not WT) T cells had significantly
lower weight by week 1 that persisted up to week 6 after
T-cell transfer (Figure 1B). No differences in the amount
of stool blood or consistency were found (data not
shown). We observed that constitutive TL1A expression
led to reduced weight in the adoptive T-cell transfer
model.
lated fro
 0.05,
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Mice
Inspection of the gut revealed increased gross inflamma-
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of both Tl1a-Tg models than from WT mice (Figure 1E).
Histological examination of the intestine revealed
blunting of the villi, crypt damage, worsened inflamma-
tory changes, and increased mononuclear cell infiltration
of the lamina propria (LP), particularly in the ileum from
Tl1a-Tg compared to WT mice in both the DSS (Figure
2A) and adoptive-transfer models (Figure 2C). Depend-
ing on the murine colitis model used, different intestinal
areas with increased inflammatory changes were ob-
served. For example, histological changes were re-
flected by a significant increase in the inflammatory
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AJP February 2012, Vol. 180, No. 2WT and Tl1a-Tg mice in both chronic colitis models. In the
DSS-induced colitis model, enhanced inflammation was
observed in the Tl1a-Tg compared to WT cecum but no
other colonic regions (Figure 3A and data not shown).
In the adoptive T-cell transfer model, proximal migra-
tion of colonic inflammation was observed in T cells from
Rag1/mice transferred with Tl1a-Tg compared to WT T
cells (Figure 3B). Compared to WT mice, there was ex-
acerbation of cecal inflammation but relative sparing of
rectal inflammation in Tl1a-Tg mice (Figure 3B). Closer
inspection of colonic specimens revealed increased hy-
peremia, wall thickening, edema, and adhesions in the
cecum with relative sparing in the rectum in the Rag1/
mice transferred with Tl1a-Tg compared to WT T cells
(Figure 3C). These data showed constitutive TL1A ex-
pression led to proximal migration of colonic inflammation
with relative rectal sparing in the adoptive T-cell transfer
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L-Tg, 1 of 14; M-Tg, 1 of 15) and in the adoptive T-cell
transfer model (WT, 0 of 12; L-Tg, 1 of 14). An example
of hydronephrosis with ureteral stricture is shown in
Figure 4B.
To determine whether there was increased collagen
deposition, Masson-Trichrome stain was performed on
colonic and intestinal regions without gross stricture. In-
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collagen deposition was found in the nonstrictured colon
in Rag1/ mice transferred with Tl1a Tg T cells (Figure
5A). Collagen deposition was not different in the nonstric-
tured ilea (Figure 5A). Increased numbers of vimentin-
positive cells were observed in both the nonstrictured
ileum and colon of Rag1/mice transferred with Tl1a-Tg
than with WT T cells (Figure 5B).
As increased colonic mRNA expression of pro-fibro-
genic factors TGF-1 and IGF-1 in CD patients had been
reported,24,25 the expression of these genes was as-
sessed. Compared to WT mice (1.1%  0.34% actin),
increased expression of colonic TGF-1 in the L-Tg
(2.0%  0.94%, P  0.02 versus WT) and M-Tg mice
(2.29%  1.4% actin, P  0.02 versus WT) undergoing
chronic DSS treatment was found in the nonfibrotic co-
lonic sections. The expression of TGF-1 in the intestine
was not different between WT and Tl1a-Tg mice (data not
shown). No difference in the expression of IGF-1 was
detected in both chronic colitis models (data not shown).
Together, these results demonstrated that constitutive
TL1A expression in T cells and myeloid cells led to severe
fibrostenotic disease in the murine gut, which may in part
be due to elevated expression of the pro-fibrogenic factor
TGF-1.Accelerated T-Cell Activation and Enhanced
IL-17 Production in the Chronic DSS Colitis
Model
To assess the effect of TL1A expression on immune-cell
composition, we performed flow cytometric analysis.
Flow cytometry did not reveal differences in the frequen-
cies of CD3, CD4, CD8, CD11c, or F4/80 cells in
the spleen and MLN between L-Tg, M-Tg, or WT litter-
mate mice (data not shown). To determine the effect of
constitutive TL1A expression on the activation state of
antigen-presenting cells, the expression of the activation
marker CD86 was compared. Flow cytometry did not
reveal differences in the CD86 expression between den-
dritic cells (CD11c) and macrophages (F4/80) be-
tween Tl1a-Tg and WT mice (data not shown). Similar
frequencies of T cells expressing the gut-homing markers
chemokine receptor-9 and chemokine receptor-10 were
found (data not shown).
To assess whether constitutive TL1A expression can
enhance the co-stimulation of T cells in the DSS model,
we compared the expression of CD44 on CD4 and
CD8 cells between Tg and WT littermate controls.
Figure 5. Adoptive transfer of L-Tg mice can
lead to fibrostenotic disease. A: Masson-
Trichrome staining of collagen deposition in
nonstrictured tissue sections of mouse at mid-
colon and distal 3 cm of ilea is shown for the
adoptive-transfer model. Thickness of collagen
deposition was quantitated and represented as
mean  SD. B: Vimentin stain of fibroblasts in
nonstrictured tissue sections was performed for
the adoptive-transfer model. Fibroblasts were
stained brown (arrows). Vimentin-positive cells
were quantitated and represented as mean 
SD. Fields were scored at200 magnification for
A and B. *P  0.05, **P  0.01.CD4CD45RBlowCD25 Treg cells were gated out to ex-
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tional T cells. Compared to WT mice, a higher percentage
of Tl1a-Tg CD4 and CD8 cells expressed the activa-
tion marker CD44, particularly in the L-Tg mice (Figure 6).
To assess the molecular consequences of increased
T-cell activation in the Tl1a-Tg mice, the expression of
IFN-, interleukin (IL)-13, and IL-17 was measured. Fig-
ure 7A shows increased frequency of CD4IL-17 T cells
in Tl1a-Tg mice compared to WT mice that reached sig-
nificance in the frequency of CD4IL-17 in the MLN (WT
0.6  0.2 versus L-Tg 6.0  2.8, P  0.03; WT 0.6  0.2
versus M-Tg 4.0  1.9, P  0.04). No difference in the
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Figure 6. Sustained TL1A expression leads to increased percentage of acti-
vated T cells in DSS-induced chronic colitis. Flow cytometry plot of spleno-
cytes and MLN cells showing expression of activation markers CD44. CD4
and CD8 cells were gated as indicated. Data shown are representative of at
least five independent experiments.proportion of CD4IL-13 and CD4FN- cells wasfound. Similar to what was shown with intracellular stain-
ing; higher IL-17 production in the MLN for both Tl1a-Tg
mice was found (Figure 7B). No differences in the pro-
duction of IFN-, IL-13, TNF, or IL-6 were observed
(Figure 7B and data not shown).
Constitutive TL1A Expression Leads to
Enhanced Th-1 but Reduced Th-17 Immune-
Responses in the Adoptive T-Cell Transfer
Model
In the adoptive T-cell transfer model, no differences in the
frequencies of CD3, CD4, chemokine receptor-9 and
-10, activation markers (CD44 and CD86), CD11c, or
F4/80 cells in the spleen, and MLN between Rag1/
mice transferred with WT or Tl1a-Tg T cells were ob-
served (data not shown). Intracellular cytokine staining
showed that the frequency of CD4IFN- was signifi-
cantly elevated in the spleen (WT 7.7  0.9 versus L-Tg
11.1 1.5, P 0.03) and MLN (WT 9.5 0.8 versus L-Tg
13.1  2.0, P  0.04) of Rag1/ mice transferred with T
cells expressing TL1A compared to WT T cells (Figure
8A). There were very low numbers of CD4IL-17 T cells
in Rag1/ mice transferred with Tl1a-Tg T cells in the
spleen (WT 11.5  3.4 versus L-Tg 4.4  2.1, P  0.04)
and MLN (WT 18.3 2.2 versus L-Tg 1.7 1.2, P 0.01)
(Figure 8A). No differences in the frequency of
CD4IL13 cells were found (Figure 8A).
Consistent with the results from intracellular staining,
higher IFN- production was found in the spleen, MLN,
and LPMC in Rag1/ mice transferred with Tl1a-Tg T
cells compared to WT T cells (Figure 8B). Significantly
reduced IL-17 production was observed in all of the tis-
sues tested (Figure 8B). No differences in the production
of IL-13, TNF, and IL-6 were observed (Figure 8B and
data not shown). These data indicated that constitutive
expression of TL1A in naive CD4CD45RBhi T cells may
affect the proliferation, differentiation, or maintenance of
Th-1 and -17 cells in the peripheral immune compart-
ments and inflamed tissues.
Proximal Migration of Colonic Inflammation
with Relative Rectal Sparing and Intestinal
Fibrostenosis in High TL1A Expressing CD
Patients
Given the findings in mice, we examined whether humans
with elevated TL1A expression had similar proximal mi-
gration of colonic inflammation with relative rectal spar-
ing. A blinded retrospective analysis of CD patients with
known TL1A expression in peripheral monocytes was
performed.3 In our previous study, TL1A level of 0.15
ng/mL/1  106 peripheral monocytes at 6 hours post
immune complex stimulation distinguished over 90% of
Jewish CD patients with risk TL1A haplotype-B and pro-
tective haplotype-A.3 Therefore, high TL1A producers
were defined as subjects with homozygous risk haplo-
type-B whose immune complex–stimulated TL1A at 6
hours was 0.15 ng/mL/1  106 peripheral monocytes,
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haplotype-A whose immune complex–stimulated TL1A
at 6 hours was 0.15 ng/mL/1  106 peripheral mono-
cytes. The patients’ demographics, clinical features,
and medications within 2 months of colonoscopy are
provided in Table 1. Significant increases in intestinal
strictures and in scores from the Harvey-Bradshaw
Index were found in the high-TL1A compared to the
low-TL1A group (Table 1).
To assess whether TL1A expression level is associ-
ated with a specific mucosal pattern of inflammation,
H&E-stained histological sections from ileum, cecum,
sigmoid, and rectum were examined. Compared to the
low-TL1A group, the high-TL1A group had more severe
ileocecal inflammation with relative rectosigmoid spar-
ing of inflammation (Figure 9). Together, these data
suggest that CD patients who express elevated TL1A
levels develop worsened inflammation in the ileoco-lonic region and proximal migration of colonic inflam-
mation with relative sparing of inflammation in the sig-
moid and rectum.
Discussion
This study shows that constitutive TL1A expression
resulted in severe patchy intestinal inflammation with
proximal migration of colonic inflammation under coli-
togenic conditions. Furthermore, Tl1a-Tg mice sponta-
neously developed ileitis, but not colitis, by 10 months
of age.15–17 The severity of ileitis was more dramatic in
these induced chronic colitis models. As colitis is the
predominant gut pathology seen in both the DSS and
adoptive-transfer models, the ileitis reported in this
study was likely driven by constitutive TL1A expres-
Figure 7. Sustained TL1A expression leads to
increased IL-17 expression in DSS-induced
chronic colitis. A: Flow cytometry plots of
gated CD4 cells from spleen and MLN,
stained for intracellular IFN-, IL-17, and IL13
expression, are shown. Data shown are repre-
sentative of 5 mice per group. B: IFN-, IL-
17, and IL13 secretion after stimulation with
anti-CD3 and anti-CD28 were assessed by en-
zyme-linked immunosorbent assay. Each data
point represents cytokine expression for
splenocytes, MLN cells, or LPMC from an in-
dividual mouse. P values are indicated where
significant.sion. Depending on the model, TL1A expression led to
ti-CD28
dividua
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duodenum (adoptive-transfer). Constitutive TL1A ex-
pression also altered the colitis pattern from the more
distal rectosigmoid inflammation to the more proximal
cecal inflammation. These inflammatory changes were
likely caused by TL1A and not the cell type that ex-
presses TL1A as both L-Tg and M-Tg mice exhibited a
similar pattern of inflammation. Relative sparing of rec-
tal inflammation was seen in the adoptive-transfer
model using Tl1a-Tg T cells. TNFSF15 is a severity
gene, which when overexpressed results in a change
in location to the proximal parts of the colon and small
intestine, and away from the rectum.
Prior studies reported that TL1A is associated with
expansion of T-helper subsets and can synergize with
IL-12 and -18 to enhance Th-1 response and IFN-
production.6,7,26,27 Other investigations found that
mice lacking TL1A display reduced experimental en-
cephalitis disease activity that is associated with de-
creased Th-17 cell differentiation and proliferation.9
Consistently, in DSS-induced models of chronic colitis,
TL1A enhances Th-1 and Th-17 effector functions by
up-regulating IFN- and IL-17 production, respec-
Figure 8. Sustained TL1A expression leads to increased IFN- and reduced
CD4 cells from spleen and MLN, stained for intracellular IFN-, IL-17, and
B: IFN-, IL-17, and IL13 secretion after stimulation with anti-CD3 and an
represents cytokine expression for splenocytes, MLN cells, or LPMC of an intively, in CD4 T cells under Th-1/Th-17 polarizingconditions.10 TL1A had also been found to be involved
in Th-2–mediated ova-induced lung disease and in
spontaneous ileitis.8,15,16 These reports indicated that
the TL1A/DR3 signaling pathway might have a univer-
sal role in regulating T-helper effector outcomes.
In line with our previous report,10 increased IL-17
production was found in DSS-induced chronic colitis
with constitutive TL1A expression. In the adoptive-
transfer model, TL1A expression led to a Th-1–domi-
nant immune response with almost a complete ab-
sence of IL-17 production. The differences in the
T-helper response may be based on the differentiation
state of the CD4 T cells. In the DSS-induced chronic
colitis model, TL1A can enhance the effector charac-
teristics of committed Th-17 cells. In the adoptive-
transfer model, TL1A/DR3 signaling may inhibit Th-17
development in newly challenged naive T cells. Differ-
ential responsiveness of naive and committed T cells to
TL1A/DR3 signaling had also been recently pro-
posed.12
Another explanation for the difference in the TL1A-
dependent T-helper immune response between the
DSS and adoptive T-cell transfer models may be dif-
xpression in the adoptive-transfer model. A: Flow cytometry plots of gated
pression, are shown. Data shown are representative of 5 mice per group.
were assessed by enzyme-linked immunosorbent assay. Each data point
l mouse. P values are indicated where significant.IL-17 e
IL13 exferent gut microflora. We bred WT and Tl1a-Tg litter-
le; M, m
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experiments. For the adoptive-transfer model, we pur-
chased Rag1/ recipient mice from Jackson Labora-
tory (Bar Harbor, ME). Previous studies had demon-
Table 1. Summary of Clinical and Laboratory Data
High TL1A
Sex (M/F) 4/4
SB stricture 62.5% (5/8)
Colon stricture 12.5% (1/8)
Biologic use 25% (2/8)
Failed 1 biologic* 62.8% (5/8)
Failed 2 biologics* 25% (2/8)
Immunomodulator† use 27.5% (3/8)
Immunomodulator† failure 75%(6/8)
5-ASA‡ failure 87.5% (7/8)
Enema use 0%
Ureteral stricture 25% (2/8)
Previous surgery 87.5% (7/8)
TL1A (ng/mL) 0.29 0.12
Harvey-Bradshaw Index 9 3.45
Time to surgery (years) 11 10.0
WBC (100/L) 8.40  4.34
ESR (mm/hour) 20.64  15.3
CRP (mg/dL) 1.17 1.59
Data are expressed as percentages with n/total or as the mean  SD
*Biologics include infliximab, adalimumab, certolizumab, thalidomide,
†Immunomodulators include azathioprine, 6-mercaptopurine, methotr
‡5-ASAs include mesalamine and sulfasalazine.
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; F, fema
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different TL1A-mediated T-helper immune response.
Compared to WT mice, increased collagen deposition
was observed in older Tl1a-Tg mice.17 Notably, the se-
verity of fibrosis was worse in the induced chronic colitis
models with constitutive TL1A expression where gross
(not just histological) colonic and intestinal strictures
were observed. This may reflect the fact that the induced
chronic colitis models led to an accelerated T-helper
effector function in which the effector phase of the dis-
ease is reached earlier. In addition, TL1A may be ex-
pressed by an independent pro-fibrogenic gene to initi-
ate the process of fibrosis since we previously found that
TL1A expression resulted in increased colonic collagen
deposition in the absence of detectable histological in-
flammation.17 Furthermore, in the current study, visible
colonic strictures were observed in the mid-colon of only
the Tl1a-Tg mice despite a similar degree of inflammation
as compared to WT mice (Figures 3 and 4). The pro-
fibrotic effects of TL1A may be mediated by TGF-1 as its
expression was increased in the nonstrictured colon of
Tg compared to WT mice (Figure 5C). However, other
factors are likely involved and need to be explored fur-
ther. To our knowledge, these Tl1a-Tg animal models are
the only in vivo model in which overexpression of a single
IBD-associated gene lead to gross intestinal and colonic
fibrostenotic disease that is characteristic of some forms
of CD.
Compared to CD patients with low TL1A expression,
higher TL1A-producing CD patients had increased in-
flammation in the ileum and cecum with reduced in-
flammation in the sigmoid and rectum (Figure 9). None
of the CD patients in our study cohort used rectally
administered IBD therapy; therefore, the reduction in
rectosigmoid inflammation may be due to elevated
TL1A expression. A significantly higher rate of intesti-
nal strictures was found in CD patients with higher
TL1A levels (Table 1), suggesting that TL1A may in-
duce intestinal strictures in humans. This is consistent
with previous reports showing that TNFSF15 haplo-
type-B, which is associated with increased TL1A lev-
els, is also characterized by the increased need for
surgery due to fibrostenotic CD disease.3,4 One limita-
tion of the retrospective analysis is the small sample
size, thus our findings need to be confirmed in an
independent prospective study.
Extraintestinal manifestations of CD can include ar-
thropathy, erythema nodosum, and more rarely, hydro-
nephrosis due to strictures along the genitourinary
tract.1,31,32 The presence of IBD-like skin lesions and
arthropathy in older Tl1a-Tg mice were reported.17 In
this study, hydronephrosis due to ureteral strictures
was only observed in Tl1a-Tg mice during the devel-
opment of chronic colitis (7%, 3 of 43). Ureteral involve-
ment has been reported to occur in 3% to 6% of CD
cases.32 Interestingly, a higher frequency of ureteral
stricturing was found in our small cohort of CD patients
expressing higher TL1A levels (25%, 2 of 8, Table 1),
suggesting that TL1A may also cause ureteral fibrosis.
In summary, TL1A modulates the severity and location
of inflammation in the intestine and colon under colito-genic conditions. Sustained TL1A expression also in-
duces stricturing disease in the gut that is caused by
increased collagen deposition and number of fibroblasts.
Results from these Tl1a-Tg experimental models coupled
with findings in CD patients suggest that TNFSF15 is a
severity gene and that the cytokine TL1A, when overex-
pressed, plays a central role in generating one pheno-
typic form of complicated CD.
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